Literature DB >> 3941781

Azathioprine toxicity in neuromuscular disease.

J T Kissel, R J Levy, J R Mendell, R C Griggs.   

Abstract

Azathioprine toxicity was examined in 64 consecutively treated patients with various neuromuscular diseases. Reversible leukopenia was seen in 14 patients (22%). Hepatotoxicity developed in six patients (9%), and a systemic reaction characterized by fever, abdominal pain, nausea, vomiting, and anorexia occurred in eight patients (12%). Toxic effects limited the dose of azathioprine in 27 patients (42%) and led to discontinuation of therapy in 13 (20%). Macrocytosis developed in 20% of patients, but did not require an adjustment in the dose. Two patients received allopurinol and azathioprine; both developed reversible leukopenia and macrocytosis. Patients with hematologic and hepatic toxicity, but not those with systemic toxicity, successfully tolerated retreatment with azathioprine. Toxicity was delayed as long as 56 weeks after starting azathioprine in some patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941781     DOI: 10.1212/wnl.36.1.35

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Paraneoplastic Diseases of the Nervous System.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

Review 4.  Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

Authors:  Anne Louise Oaklander; Michael Pt Lunn; Richard Ac Hughes; Ivo N van Schaik; Chris Frost; Colin H Chalk
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

Review 5.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

6.  Phase II trial of methotrexate in myasthenia gravis.

Authors:  Mamatha Pasnoor; Jianghua He; Laura Herbelin; Mazen Dimachkie; Richard J Barohn
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

7.  Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis.

Authors:  F Mion; B Napoleon; F Berger; M Chevallier; S Bonvoisin; L Descos
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

8.  Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis.

Authors:  M E Jeurissen; A M Boerbooms; L B van de Putte; M W Kruijsen
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

Review 9.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

10.  Vasculitic Neuropathies.

Authors:  Elie Naddaf; P James Bonham Dyck
Journal:  Curr Treat Options Neurol       Date:  2015-10       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.